近日，中國(guó)藥科大學(xué)韓超課題組趙雨老師，使用IPHASE品牌產(chǎn)品：人CD4+T細(xì)胞、人pbmc、小鼠CD4+T細(xì)胞在《Acta Pharmaceutica Sinica B》權(quán)-威期刊上發(fā)表文章《LSD1 inhibition sensitizes anti-PD1 blockade immunotherapy by inhibiting the long-range attack of tumor-derived extracellular vesicles》，影響因子14.6！

摘要

Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genomewide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatinDNA binding and sensitizes

完整版文獻(xiàn)可在【IPHASE】公眾號(hào)后臺(tái)留言【獲取文章】

再次恭喜文獻(xiàn)發(fā)表，以及對(duì)我司產(chǎn)品的認(rèn)可，希望以上文獻(xiàn)能幫助大家了解目前研究進(jìn)展及我們的核心技術(shù)，歡迎各位新老客戶聯(lián)系我們咨詢、提出意見(jiàn)，愿我們的努力成果與您的科研碰撞出不一樣的火花！